Domingo Granero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Domingo Granero has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jose Perez-Calatayud
Radiation Oncology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
27 shared publications F Ballester
CHU de Quebec, Quebec, QC
18 shared publications- Facundo Ballester
IRIMED, IIS-La Fe-Universitat de Valencia (UV), 46100 Burjassot, Spain
12 shared publications - Javier Vijande
Departamento de Física Atómica, Molecular y Nuclear, Universitat de Valencia (UV), Burjassot, Spain
11 shared publications - E. Casal
University of Valencia
9 shared publications - J. Richart
Clinica Benidorm, Benidorm, Alicante
5 shared publications
Latest Publications
- 14 February 2021
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (8) , 1657-1665
Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project
Purpose RENORT is a novel data mining application developed to extract relevant clinical data from oncology information systems (OIS; ARIA and Mosaiq) used in radiation oncology (RO). Methods/patients We used RENORT to extract demographic and clinical data from the OIS of all patients treated at the RO Department at the General Hospital of Valencia during the year 2019. Results A total of 1158 treatments were performed. The female/male ratio was 39.3%/60.7%, with a mean age of 66 years. The mean waiting time between the treatment decision/proposal to the first visit was 10.1 days. Mean duration of the treatment preparation process was 21 days. Most patients (90.4%) completed treatment within the prescribed time ± 7 days. The most common sites/treatment types were: metastatic/palliative treatments (n = 300; 25.9%), breast (209; 18.0%), genitourinary (195; 16.8%), digestive (116; 10.0%), thoracic (104; 9.0%), head and neck (62; 5.4%), and skin cancer (51; 4.4%). The distribution according to treatment intent was as follows: palliative (n = 266; 23.0%), adjuvant curative (335; 28.9%), radical without adjuvant treatment (229; 19.8%), radical with concomitant treatment (188; 16.2%), curative neoadjuvant (70; 6.0%), salvage radiotherapy (61; 5.3%); and reirradiation (9; 0.8%). The most common treatment techniques were IMRT/VMAT with IGRT (n = 468; 40.4%), 3D-CRT with IGRT (421; 36.4%), SBRT (127; 11.0%), 2DRT (57; 4.9%), and SFRT (56; 4.8%). A mean of 15.9 fractions were administered per treatment. Hypofractionated schemes were used in 100% of radical intent breast and prostate cancer treatments. Conclusions The RENORT application facilitates data retrieval from oncology information systems to allow for a comprehensive determination of the real role of radiotherapy in the treatment of cancer patients. This application is valuable to identify patterns of care and to assess treatment efficacy.
- 14 February 2021
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (8) , 1657-1665
Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project
Purpose RENORT is a novel data mining application developed to extract relevant clinical data from oncology information systems (OIS; ARIA and Mosaiq) used in radiation oncology (RO). Methods/patients We used RENORT to extract demographic and clinical data from the OIS of all patients treated at the RO Department at the General Hospital of Valencia during the year 2019. Results A total of 1158 treatments were performed. The female/male ratio was 39.3%/60.7%, with a mean age of 66 years. The mean waiting time between the treatment decision/proposal to the first visit was 10.1 days. Mean duration of the treatment preparation process was 21 days. Most patients (90.4%) completed treatment within the prescribed time ± 7 days. The most common sites/treatment types were: metastatic/palliative treatments (n = 300; 25.9%), breast (209; 18.0%), genitourinary (195; 16.8%), digestive (116; 10.0%), thoracic (104; 9.0%), head and neck (62; 5.4%), and skin cancer (51; 4.4%). The distribution according to treatment intent was as follows: palliative (n = 266; 23.0%), adjuvant curative (335; 28.9%), radical without adjuvant treatment (229; 19.8%), radical with concomitant treatment (188; 16.2%), curative neoadjuvant (70; 6.0%), salvage radiotherapy (61; 5.3%); and reirradiation (9; 0.8%). The most common treatment techniques were IMRT/VMAT with IGRT (n = 468; 40.4%), 3D-CRT with IGRT (421; 36.4%), SBRT (127; 11.0%), 2DRT (57; 4.9%), and SFRT (56; 4.8%). A mean of 15.9 fractions were administered per treatment. Hypofractionated schemes were used in 100% of radical intent breast and prostate cancer treatments. Conclusions The RENORT application facilitates data retrieval from oncology information systems to allow for a comprehensive determination of the real role of radiotherapy in the treatment of cancer patients. This application is valuable to identify patterns of care and to assess treatment efficacy.
- 3 July 2020
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (3) , 481-490
Patterns of treatment failure in patients with prostate cancer treated with 76–80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy
Purpose To assess the pattern of treatment failure in patients with prostate cancer (PCa) treated with radiotherapy (76–80 Gy) ± hormone therapy (HT). We also evaluated the influence of treatment failure on survival outcomes. Methods Retrospective study of patients with PCa (n = 302) treated with radiotherapy (RT) ± HT at our centre between November 1999 and July 2007. The mean patient age was 70.2 years (range 51–87). Distribution by NCCN risk group was low (n = 80, 26.5%), intermediate (n = 86, 28.5%), high (n = 77, 25.5%), and very high (n = 49, 16.2%). Most patients (n = 273, 90.4%) received IMRT at a dose of 76–80 Gy. HT was administered in 237 patients (78.5%), in most cases (n = 167, 55.3%) for < 7 months Results Survival rates at 10 years were: overall survival (OS), 64.3%; biochemical disease-free survival, 83.9%; disease-free survival, 92.5%; and metastasis-free survival (MFS), 94.3%. Biochemical failure (BF) was observed in 55 cases (18.2%), 32 of whom subsequently developed clinical recurrence: metastasis (n = 17, 5.6%), local failure (n = 11, 3.6%), and regional failure (n = 4, 1.3%). The cause of death (n = 159) was intercurrent disease in 115 cases (72.3%), second cancer in 27 (17.0%), and PCa in 17 (10.7%). Biochemical failure-free survival ≤ 24 months was significantly associated with worse OS and MFS (p = 0.0001). Late genitourinary and gastrointestinal toxicity grade ≥ 3 (RTOG) was observed in 18 (6.0%) and 7 (2.3%) patients, respectively. Conclusions The main type of treatment failure after 76–80 Gy of radiotherapy ± HT is local or metastatic. In all cases, biochemical failure occurred prior to treatment failure. BF within 24 months of treatment completion was significantly associated with worse OS and MFS.
- 3 July 2020
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (3) , 481-490
Patterns of treatment failure in patients with prostate cancer treated with 76–80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy
Purpose To assess the pattern of treatment failure in patients with prostate cancer (PCa) treated with radiotherapy (76–80 Gy) ± hormone therapy (HT). We also evaluated the influence of treatment failure on survival outcomes. Methods Retrospective study of patients with PCa (n = 302) treated with radiotherapy (RT) ± HT at our centre between November 1999 and July 2007. The mean patient age was 70.2 years (range 51–87). Distribution by NCCN risk group was low (n = 80, 26.5%), intermediate (n = 86, 28.5%), high (n = 77, 25.5%), and very high (n = 49, 16.2%). Most patients (n = 273, 90.4%) received IMRT at a dose of 76–80 Gy. HT was administered in 237 patients (78.5%), in most cases (n = 167, 55.3%) for < 7 months Results Survival rates at 10 years were: overall survival (OS), 64.3%; biochemical disease-free survival, 83.9%; disease-free survival, 92.5%; and metastasis-free survival (MFS), 94.3%. Biochemical failure (BF) was observed in 55 cases (18.2%), 32 of whom subsequently developed clinical recurrence: metastasis (n = 17, 5.6%), local failure (n = 11, 3.6%), and regional failure (n = 4, 1.3%). The cause of death (n = 159) was intercurrent disease in 115 cases (72.3%), second cancer in 27 (17.0%), and PCa in 17 (10.7%). Biochemical failure-free survival ≤ 24 months was significantly associated with worse OS and MFS (p = 0.0001). Late genitourinary and gastrointestinal toxicity grade ≥ 3 (RTOG) was observed in 18 (6.0%) and 7 (2.3%) patients, respectively. Conclusions The main type of treatment failure after 76–80 Gy of radiotherapy ± HT is local or metastatic. In all cases, biochemical failure occurred prior to treatment failure. BF within 24 months of treatment completion was significantly associated with worse OS and MFS.
- 4 April 2016
- Published by Wiley in Medical Physics
- Vol. 43 (5) , 2087-2090
Technical Note: Dosimetry of Leipzig and Valencia applicators without the plastic cap
Purpose: High dose rate (HDR) brachytherapy for treatment of small skin lesions using the Leipzig and Valencia applicators is a widely used technique. These applicators are equipped with an attachable plastic cap to be placed during fraction delivery to ensure electronic equilibrium and to prevent secondary electrons from reaching the skin surface. The purpose of this study is to report on the dosimetric impact of the cap being absent during HDR fraction delivery, which has not been explored previously in the literature. Methods: geant4Monte Carlo simulations (version 10.0) have been performed for the Leipzig and Valencia applicators with and without the plastic cap. In order to validate the Monte Carlo simulations, experimental measurements using radiochromic films have been done. Results: Dose absorbed within 1 mm of the skin surface increases by a factor of 1500% for the Leipzig applicators and of 180% for the Valencia applicators. Deeper than 1 mm, the overdosage flattens up to a 10% increase. Conclusions: Differences of treating with or without the plastic cap are significant. Users must check always that the plastic cap is in place before any treatment in order to avoid overdosage of the skin. Prior to skin HDR fraction delivery, the timeout checklist should include verification of the cap placement.
- 4 April 2016
- Published by Wiley in Medical Physics
- Vol. 43 (5) , 2087-2090
Technical Note: Dosimetry of Leipzig and Valencia applicators without the plastic cap
Purpose: High dose rate (HDR) brachytherapy for treatment of small skin lesions using the Leipzig and Valencia applicators is a widely used technique. These applicators are equipped with an attachable plastic cap to be placed during fraction delivery to ensure electronic equilibrium and to prevent secondary electrons from reaching the skin surface. The purpose of this study is to report on the dosimetric impact of the cap being absent during HDR fraction delivery, which has not been explored previously in the literature. Methods: geant4Monte Carlo simulations (version 10.0) have been performed for the Leipzig and Valencia applicators with and without the plastic cap. In order to validate the Monte Carlo simulations, experimental measurements using radiochromic films have been done. Results: Dose absorbed within 1 mm of the skin surface increases by a factor of 1500% for the Leipzig applicators and of 180% for the Valencia applicators. Deeper than 1 mm, the overdosage flattens up to a 10% increase. Conclusions: Differences of treating with or without the plastic cap are significant. Users must check always that the plastic cap is in place before any treatment in order to avoid overdosage of the skin. Prior to skin HDR fraction delivery, the timeout checklist should include verification of the cap placement.
- 29 June 2015
- Published by Wiley in Medical Physics
- Vol. 42 (6Part41) , 3707
TH‐AB‐BRA‐02: Generation of 3D Dosimetric Reference Datasets for Commissioning and Validation of 192Ir Brachytherapy Model‐Based Dose Calculation Software
- 29 June 2015
- Published by Wiley in Medical Physics
- Vol. 42 (6Part41) , 3707
TH‐AB‐BRA‐02: Generation of 3D Dosimetric Reference Datasets for Commissioning and Validation of 192Ir Brachytherapy Model‐Based Dose Calculation Software
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part28) , 475-476
WE-C-108-08: Organ Doses in a Male Phantom Undergoing High-Dose-Rate Brachytherapy Applied to the Prostate
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part28) , 475-476
WE-C-108-08: Organ Doses in a Male Phantom Undergoing High-Dose-Rate Brachytherapy Applied to the Prostate
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part18) , 324
SU-E-T-516: Limitations and Clinical Implications of the TG-43 Formalism for High-Dose-Rate Skin Brachytherapy
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part18) , 324
SU-E-T-516: Limitations and Clinical Implications of the TG-43 Formalism for High-Dose-Rate Skin Brachytherapy
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part18) , 322
SU‐E‐T‐508: Monte Carlo Dosimetric Study of the CSM40 Low Dose Rate Source
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part18) , 322
SU‐E‐T‐508: Monte Carlo Dosimetric Study of the CSM40 Low Dose Rate Source
- Open Access
- 1 March 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106, S448
EP-1186: Accuracy of the TG-43 dose calculation formalism for HDR skin brachytherapy
- 1 March 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106, S448
Open AccessEP-1186: Accuracy of the TG-43 dose calculation formalism for HDR skin brachytherapy
- 1 January 2013
- Published by Elsevier in Physica Medica
- Vol. 29 (1) , 60-64
Radiation leakage study for the Valencia applicators
- 1 January 2013
- Published by Elsevier in Physica Medica
- Vol. 29 (1) , 60-64
Radiation leakage study for the Valencia applicators
- 28 June 2012
- Published by Wiley in Medical Physics
- Vol. 39 (6Part17) , 3812
SU-E-T-467: Monte Carlo Dosimetric Study of the New Flexisource Co-60 High Dose Rate Source
Dosimetric data are provided for the new Flexisource Co-60 source not studied previously in the literature. Using the data provided by this study in the treatment planning systems, it can be used in clinical practice. This project has been funded by Nucletron BV.
- 28 June 2012
- Published by Wiley in Medical Physics
- Vol. 39 (6Part17) , 3812
SU-E-T-467: Monte Carlo Dosimetric Study of the New Flexisource Co-60 High Dose Rate Source
Dosimetric data are provided for the new Flexisource Co-60 source not studied previously in the literature. Using the data provided by this study in the treatment planning systems, it can be used in clinical practice. This project has been funded by Nucletron BV.